Tag: Trastuzumab deruxtecan

Results from a global Phase 3 trial demonstrated that trastuzumab deruxtecan (T-DXd; Enhertu®; Daiichi Sankyo and AstraZeneca) can delay disease progression longer than standard...

August 2026 was a busy month for the antibody-drug conjugate (ADC) field, with activity spanning the full arc of development. Highlights included early discovery partnerships, manufacturing alliances, a practice-changing phase 3 readout in lung cancer, and the first dosing of a novel Treg-depleting ADC.

Practice-Changing Advances in Early HER2-Positive Breast Cancer: ASCO 2026 and FDA Approvals Establish Trastuzumab Deruxtecan as a New Standard

Advances, Sequencing Challenges, and Real-World Integration of ADCs in Breast Cancer: Insights from ASCO 2026

ASCO, the American Society of Clinical Oncology, has expanded the Targeted Agent and Profiling Utilization Registry (TAPUR™) study. The TAPUR study (NCT02693535), a phase 2...

Economy: Failure to Reshore Pharmaceutical Manufacturing: US Approved Drug Manufacturing Shifts to Europe as US Deal Volume Drops

Antibody-Drug Conjugates in Gastric Cancer: Clinical Progress, Resistance, and the Road Ahead

The U.S. Food and Drug Administration (FDA) has approved additional indications for the Roche PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody and VENTANA HER2 Dual ISH DNA Probe Cocktail tests.

Compelling evidence presented at the European Society of Medical Oncology (ESMO) Congress, being held October 17-21, 2025, in Berlin, Germany, has shown that a new generation of antibody-drug conjugates (ADCs) can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer.

The international phase 3 DESTINY-Gastric04 clinical trial (NCT04704934), sponsored  by Daiichi Sankyo, found that second-line treatment with trastuzumab deruxtecan (Enhertu®; also known as T-DXd; DS-8201; Daiichi Sankyo and AstraZeneca, See ADC Drugmap) can help people with advanced human epidermal growth factor receptor 2 (HER2-) positive (IHC 3+ or IHC 2+/ISH+) unresectable and/or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJA) that have grown during first-line treatment live about 3 months longer. The study outcomes demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to ramucirumab (Cyramza®; Eli Lilly and Company) plus paclitaxel (Taxol®; Bristol-Myers Squibb).